Bioelectron

Bioelectron Technology Corporation, formerly known as Edison Pharmaceuticals, was a clinical-stage biotechnology company focused on the development of small molecule therapeutics for rare genetic and neurodegenerative diseases. The company's core expertise lay in redox biology and mitochondrial function, utilizing a proprietary platform to identify compounds that regulate cellular energy metabolism and oxidative stress. Its lead assets, vatiquinone (EPI-743) and troloxoxime (EPI-589), were advanced into clinical trials for conditions such as Leigh syndrome and Friedreich's ataxia. In 2019, Bioelectron was acquired by PTC Therapeutics, which integrated the company's redox technology and pipeline into its broader portfolio of treatments for rare disorders.